Viral Vector Manufacturing Market Trends, Volume, Demand, Growth and Market Forecast 2023-2030

Report Summary

Table of Content

List of Tables & Figures

Viral Vector Manufacturing Market is segmented By Type (Retroviral Vectors, Adenoviral Vectors, Adeno-Associated Viral Vectors, Other Viral Vectors), By Disease (Cancer, Genetic Disorders, Infectious Diseases, Other Diseases), By Application (Gene Therapy, Vaccinology), By End User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,2023-2030

Viral Vector Manufacturing Market Overview

[150 Pages Report] Viral Vector Manufacturing Market size was valued at USD 678.5 million in 2022 and is estimated to reach at a compound annual growth rate (CAGR) of 20.30% over the forecast period 2023 to 2030.The appropriate cells must first be grown and then transfected to produce viral vectors, typically using a plasmid formulation. The viral vector is then harvested from the cells and formulated for use, either as a gene therapy or for the medication of patient cells, such as in CAR-T cell therapies. For instance, the manufacture of adenoviral vectors, which are one of the common virus types used to deliver therapeutic genes, requires the conditions provided by adherent cell culture. In adherent cell culture, the cells are supported on a matrix of some type, with the two most typical options being microcarriers and multi-tray static plasticware.

Viral Vector Manufacturing Market Summary and Scope

Metrics	Details
Market CAGR	20.30%
Segments Covered	By Type, By Disease, By Application, By End User, and By Region
Report Insights Covered	Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region	Asia Pacific
Largest Market Share	North America

To Get a Free Sample Click here

Viral Vector Manufacturing Market Dynamics and Trends

The global viral vector manufacturing market is driven by technological advancements, the growing adoption of gene therapy, the demand for plasmid DNA, and gene therapy advancements.

Increasing demand for gene therapies drives market growth

The increasing disease burden, new product launches, and technological advancments drive the market in the forecast period. The capacity to make specific changes to the human genome offers a chance to address the root cause of dozens if not hundreds of diseases, but many worries that the transformative potential of these therapies will remain siloed to high-income countries. According to World Economic Forum, in October 2022, more than 300,000 babies were born each year with sickle cell disease. Nearly 75% of these births are in sub-Saharan Africa, and almost 17% are in the Arab-India region. Addressing these enormous health burdens will require improved screening and better primary care driving the viral vector manufacturing market worldwide.

In addition, the key players are applying the market strategies such as collaboration and product launches to expand their business. For instance, in May 2022, AGC Biologics announced that it is adding viral vector suspension technology and capacity for developing and manufacturing gene therapies at its commercial-grade campus in Longmont, Colo. Also, In October 2021, Merck launched a new viral vector contract development manufacturing facility for gene therapy to increase the scope of its global contract development and manufacturing organization. In October 2021, LEXEO Therapeutics partnered with FUJIFILM Diosynth Biotechnologies to facilitate the creation and manufacture of AAV-mediated gene treatments from LEXEO.

Furthermore, in January 2021, Fujifilm Corporation announced its plans to invest USD 40 million to build a new processing facility to produce viral vectors and related research. Moreover, in January 2021, Cobra Biologics (Charles River Laboratories) expanded its manufacturing facilities in Europe and the U.S. It includes expanding the HQ DNA manufacturing facility by four times and new facilities in Europe.

The challenges during viral vector manufacturing will hamper the market's growth.

However, while the manufacturing procedure for vaccine vectors is fairly templated, some challenges may occur since several other viruses with varying properties can be used. For large viral vectors, process sterility is required due to yield loss associated with sterile filtration. There are also challenges with vector aggregation and stability.

COVID-19 Impact on Viral Vector Manufacturing Market

The appearance of COVID-19 positively impacted the global viral vector manufacturing market. According to Cytiva Organization, Covid-19 viral vector vaccine manufacturing has placed additional pressure on the already stretched chimeric antigen receptor (CAR)-T cell therapy companies regarding the high need for key reagents. Viral vector manufacturing for gene therapies and viral vaccines, there has been a huge upsurge in demand for vaccine manufacturing capabilities since the pandemic's beginning.

Market players in CAR-T and vaccine production are fighting for the capabilities of viral vector producers, especially since these capacities are largely the same for adenoviral, lentiviral, and adeno-associated viral vector production. In addition, adenoviral vectors are used in the production of AstraZeneca's and Johnson & Johnson's Covid-19 vaccines, as well as for Russia's Sputnik-V and others. Lentiviral vectors are frequently used in CAR-T production. For instance, in April 2021, JNJ-78436735 or Ad26.COV2.S is an adenoviral vector-based vaccine against SARS-CoV-2 designed by Janssen pharmaceuticals of Johnson and Johnson in association with Beth Israel Deaconess Medical Center. European medicine agencies granted its authorization.

Viral Vector Manufacturing Market Segmentation Analysis

The adenoviral vectors segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The adenoviral vectors segment accounts for the largest market share. As per the CEVEC Pharmaceuticals 2021, viral vectors are increasingly important in diverse medical applications. Adenoviral (Ad) vectors have been employed over time among the different viral vectors. They have received continued attention due to the recent authorizations of Ad vector-based COVID-19 vaccines Vaxzevria (Oxford/AstraZeneca) and Janssen COVID-19 Vaccine (Johnson & Johnson). Also, in vaccine production, Ad vectors are used as one of the most suitable delivery tools in gene therapy applications and as oncolytic viruses.

Among the benefits of Ad vectors for vaccine production is their good safety profile, the capacity to produce a vital cellular and humoral immune response, the suitable transduction of both proliferating and quiescent cells, the comparative ease of vector construction, the potential of rapid virus production with high titers, and their stability. An essential safety feature of Ad vectors as delivery vehicles in gene therapy or vaccine production is their replication incompetence. This means that the virus, having introduced its essentials into the patient’s cells, cannot multiply disorderly.

To perform this, the Ad wild-type genome changed in different ways. The Ad E1 vectors most typically employed in gene therapy and vaccine production carry a deletion of the E1 region (400-3500), which is required for virus replication. Furthermore, the adenoviral E3 gene, which is not needed for replication, is usually deleted in these vectors, creating additional space for the transgene insertion. Increasing applications and advantages of adenoviral vectors lead to rising demand in the market.

Viral Vector Manufacturing Market Geographical Share

North America region holds the largest market share of the global viral vector manufacturing market

North America dominates the market for viral vector manufacturing and is anticipated to show a parallel trend over the forecast period. The market is propelled by factors such as advanced healthcare infrastructure, increasing research and development activities, active key players, and increasing infectious diseases.

The market players are adopting market strategies such as collaboration, product launches, and approval to expand their business. For instance, in October 2022, Kite, a Gilead Company, announced that the United States Food and Drug Administration (FDA) had approved the company's retroviral vector (RVV) manufacturing facility in California for commercial production. Viral vectors are key to manufacturing Kite's cell therapies to treat certain blood cancers. Also, in November 2020, a global contract development and manufacturing organization, Vibalogics, announced its plans to invest USD 150 million to build a 110,000-square-foot facility near Boston in the United States. The facility will produce clinical and commercial-stage oncolytic viruses and viral vectors.

Furthermore, in April 2020, AstraZeneca and Oxford University collaborated to develop a viral vaccine using the ChAdOx1 chimp adenovirus vector, a modified replication-deficient adenovirus vector. Janssen Biotech (Johnson & Johnson) also created a viral vector vaccination using a human adenovirus vector that is replication-incompetent, and the FDA approved it in February 2021.

Viral Vector Manufacturing Companies and Competitive Landscape

The viral vector manufacturing market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics (Charles River Laboratories), UniQure, Sanofi, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific, Inc., and Spark Therapeutics, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the viral vector manufacturing market globally.

For instance,

In June 2022, Avid Bioservices, Inc. opened the analytical and process development (AD/PD) suites within the company’s new, world-class viral vector development and Current Good Manufacturing Plant (CGMP) manufacturing facility. Build-out of the viral vector facility’s CGMP manufacturing suites is ongoing, with those capabilities expected to come online in mid-calendar 2023.

Lonza

Overview:

Lonza Group is a Swiss multinational manufacturing firm for the biotechnology, pharmaceutical, and nutrition sectors, founded in 1897 and headquartered in Basel, Switzerland. The company has more than 20 years of experience in viral vector manufacturing. It provides the AAV, lentivirus, and adenoviral vectors.

Product Portfolio:

AAV Production Plasmids: AAV Production Plasmids is proprietary know-how on pHelper plasmid and promoter for balanced Rep/Cap expression, higher productivity and titers, and optimized for multiple AAV serotypes and GOIs.

The global viral vector manufacturing market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.